Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.76 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.62 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364689 | 0.93 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL4379198 | 0.89 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL4366653 | 0.87 | RPS6KB1 (0.68) | MAPK14MAPK13RPS6KB1 | |
| SCHEMBL4370767 | 0.87 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL5616733 | 0.86 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3544904 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4375660 | 0.85 | RPS6KB1 (0.66) | MAPK14MAPK13RPS6KB1 | |
| SCHEMBL4368714 | 0.85 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL4367834 | 0.85 | RPS6KB1 (0.83) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 | |
| SCHEMBL3544986 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | claimed |
| EP-1824843-A2 | INHIBITORS OF PROTEIN KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2006062984-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| EP-1824843-A2 | INHIBITORS OF PROTEIN KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006062984-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K19 | MAPK14 300/4885MAPK13 418/4885MAPK12 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.